Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo

Abstract

Taken together, these results suggest that GSK-3 inhibition has the potential as a therapeutic strategy for prostate cancer intervention, although further pre-clinical and clinical testing are desirable.